HomeNBY • NYSEAMERICAN
NovaBay Pharmaceuticals Inc
$0.62
2.10%
+0.013 Today
Aug 15, 8:04:00 PM UTC-4 · USD · NYSEAMERICAN · Disclaimer
Market news
Financials
Income Statement
05M
Revenue
Net Income
Revenue
Net income
(USD)Jun 2025Y/Y change
Revenue
Operating expense
1.89M-28.51%
Net income
-1.92M-21.26%
Net profit margin
Earnings per share
EBITDA
-1.89M-81.38%
Effective tax rate
05M
Total Assets
Total Liabilities
Total assets
Total liabilities
(USD)Jun 2025Y/Y change
Cash and short-term investments
5.34M611.58%
Total assets
6.91M76.08%
Total liabilities
2.67M-41.30%
Total equity
4.25M
Shares outstanding
5.82M
Price to book
0.83
Return on assets
-56.34%
Return on capital
-75.16%
05M
Net Change in Cash
Net change in cash
(USD)Jun 2025Y/Y change
Net income
-1.92M-21.26%
Cash from operations
-2.95M-410.21%
Cash from investing
Cash from financing
-174.00K64.63%
Net change in cash
-3.12M-191.32%
Free cash flow
-2.28M-4,789.81%
StockUS listed securityUS headquartered
Previous close
$0.60
Day range
$0.54 - $0.62
Year range
$0.44 - $1.01
Market cap
3.62M USD
Avg Volume
40.74K
P/E ratio
-
Dividend yield
-
About
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on developing novel, fast-acting, synthetic anti-infectives compounds. These compounds are designed to mimic the body's defense system against infection. The company is currently focused on products for the eye care market. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis Wikipedia
Founded
2000
Employees
14
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Finance
Search
Clear search
Close search
Main menu
Google apps